British drugs giant in Italian bribery investigation
Italian prosecutors are investigating the giving of perks given to Italian doctors by the British pharmaceuticals giant GlaxoSmithKline allegedly in return for prescribing more of their drugs.
Investigating police claim they have evidence of a nationwide "bribery system" in which doctors allegedly prescribed 7-8% more Glaxo products each year in return for "freebies" such as Caribbean trips, stereo systems and wine.
In some cases, doctors received cash "gifts" ranging from £300 to £1,000, said the investigating prosecutor, Guido Papalia, in the northern town of Verona, where Glaxo has its Italian headquarters.
Glaxo played down the allegations. "We have a code of conduct and we try to follow it as scrupulously as possible," said Giuseppe Recchia, the spokesman for GlaxoSmithKline in Italy.
"Glaxo is a leader in the world pharmaceutical market. We do not need to do anything here that we do not do in other European countries," Dr Recchia said.
Dr Recchia said the company was awaiting further details of the allegations from the Italian authorities, after financial police searched 48 offices of its sales people throughout the country on February 7.
The police investigation is centred on communications between 30 doctors and 40 Glaxo salespeople between January 2001 and December 2002. Police say that emails, documents and tapped phone calls they have collected suggest more than 3,000 medical professionals may have been involved.
The investigators claim that €100m (£66m) declared by Glaxo in June 2001 as "investment to promote pharmaceuticals" was spent on free gifts - including luxury travel - for Italian doctors and other medical professionals.
But Dr Recchia argued that "travel" was not a crime, and health professionals had to attend international conferences to have the latest information on pharmaceutical developments.
Glaxo faced similar allegations in Germany last March, over allegedly offering perks such as free World Cup and formula one trips to thousands of German doctors between 1997 and 1999. The company, the biggest drugs firm in Europe, said at the time it would investigate the allegations internally and Europe-wide.
The company said at the time that many positions had been redefined and "responsibilities have changed" because of restructuring after Glaxo Wellcome merged with SmithKline Beecham in 2000.
Glaxo Wellcome was also investigated in 1995, during an Italian crackdown on corporate corruption, for allegedly bribing health ministry officials.
The head of the health ministry's pharmaceuticals department at the time, Duilio Poggiolini, cited Glaxo among several leading pharmaceutical companies which he claimed had paid bribes to secure a place in, and set their prices on, the Italian market.
Investigating police claim they have evidence of a nationwide "bribery system" in which doctors allegedly prescribed 7-8% more Glaxo products each year in return for "freebies" such as Caribbean trips, stereo systems and wine.
In some cases, doctors received cash "gifts" ranging from £300 to £1,000, said the investigating prosecutor, Guido Papalia, in the northern town of Verona, where Glaxo has its Italian headquarters.
Glaxo played down the allegations. "We have a code of conduct and we try to follow it as scrupulously as possible," said Giuseppe Recchia, the spokesman for GlaxoSmithKline in Italy.
"Glaxo is a leader in the world pharmaceutical market. We do not need to do anything here that we do not do in other European countries," Dr Recchia said.
Dr Recchia said the company was awaiting further details of the allegations from the Italian authorities, after financial police searched 48 offices of its sales people throughout the country on February 7.
The police investigation is centred on communications between 30 doctors and 40 Glaxo salespeople between January 2001 and December 2002. Police say that emails, documents and tapped phone calls they have collected suggest more than 3,000 medical professionals may have been involved.
The investigators claim that €100m (£66m) declared by Glaxo in June 2001 as "investment to promote pharmaceuticals" was spent on free gifts - including luxury travel - for Italian doctors and other medical professionals.
But Dr Recchia argued that "travel" was not a crime, and health professionals had to attend international conferences to have the latest information on pharmaceutical developments.
Glaxo faced similar allegations in Germany last March, over allegedly offering perks such as free World Cup and formula one trips to thousands of German doctors between 1997 and 1999. The company, the biggest drugs firm in Europe, said at the time it would investigate the allegations internally and Europe-wide.
The company said at the time that many positions had been redefined and "responsibilities have changed" because of restructuring after Glaxo Wellcome merged with SmithKline Beecham in 2000.
Glaxo Wellcome was also investigated in 1995, during an Italian crackdown on corporate corruption, for allegedly bribing health ministry officials.
The head of the health ministry's pharmaceuticals department at the time, Duilio Poggiolini, cited Glaxo among several leading pharmaceutical companies which he claimed had paid bribes to secure a place in, and set their prices on, the Italian market.

Use the feedback form below to submit your comments.

Use the form below to email this article to your friends.

- Schering-Plough Admits Lying To US Government
- Gates' Charity Shifts Policy
- Novartis Makes £4.4bn Move Into Cut-price Drug Making
- Investors Urge Drug Firms to Do More for World's Poor
- Aventis Braced for €60bn Bid From Its Smaller Rival
- Ruling Opens the Door for Cut-price Hiv Drugs
- Pfizer spikes cactus drug deal
- Bio-techs merge to cut costs
- Glaxo Cuts Price of Aids Drugs in Poor Countries
- Bayer insurance may not cover claims
- Novartis raises its stake in rival drugs firm Roche
- Elan looks outside lab to recruit new chief
- US Drug Makers Accused of Bullying
- Pfizer and Pharmacia set to create drugs giant
- Reno Jury Orders Wyeth to Pay $134 Million in Premarin Case
- Pharmaceutical Giant Pfizer Announces Job Cuts, Plant Closures
- Bayer 'put Asians in Danger of Hiv'



